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Leishmania amazonensis is the etiologic agent of the cutaneous and diffuse leishmaniasis. This species is often associated with drug
resistance, and the conventional treatments exhibit high toxicity for patients. Therefore, the search for new antileishmanial compounds is
urgently needed since there is no vaccine available. In this study, using the in vitro traditional drug screening test, we have analyzed the
effects of a series of diaminoalkanes monoprotected with t-butyloxycarbonyl (BOC) against L. amazonensis. Among the 18 tested
compounds, 6 exhibited antileishmanial activity (2, 7–9, 17, and 18). Best IC50 values (10.39 ± 0.27 and 3.8 ± 0.42 μg/mL) were observed
for compounds 17 and 18 (H2N(CH2)nNHBoc, n = 10 and 12), respectively. Although those compounds had higher lipophilicity as indicated
by their cLog P values, compound 17 was very toxic. Determination of the selective indexes indicated that 50% of the active compounds
were very toxic for HepG2 cells. However, compounds 2, 8, and 18 had good lipophilicity and were less toxic among all polyamine
derivatives tested. The chemical properties of antileishmanial diamine derivatives, such as lipophilicity and cytotoxicity, are relevant factors
for the design of new drugs. A higher lipophilicity is likely to improve the chances of reaching this intracellular parasite.
© 2011 Elsevier Inc. Open access under the Elsevier OA license. Keywords: Leishmania amazonensis; Diamine; BOC; Chemotherapy; Selective index1. Introduction
Leishmaniases are a spectrum of clinical manifestations
caused by the protozoan parasite Leishmania. It is estimated
that 12 million people are affected by the disease in 88
countries in Africa, Southern Europe, Central and South
America, theMiddleEast, andAsia.Leishmania (Leishmania)
amazonensis, a New World member of the Leishmania
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Open access under the Elsevier OA license. species, whose symptoms include cutaneous leishmaniasis
and diffuse cutaneous leishmaniasis (LCD). LCD is charac-
terized by a chronic, progressive, polyparasitic variant and is
manifested by disseminated nonulcerative skin lesions
(Desjeux, 2004; Herwaldt, 1999).
Although the disease is treatable, the lack of a vaccine, the
adaptation of the vector and reservoirs to human environ-
ments, and the therapeutic failure have made the control of
the disease difficult. In addition, there is no medication that is
both completely safe and efficacious for all Leishmania and
clinical manifestations (Croft et al., 2006a). In the Americas,
for over 6 decades, parenteral administration of the
pentavalent antimonials (Sb-V) sodium stibogluconate
(Pentostam®) and meglumine antimoniate (Glucantime®)
has been used for treating all types of leishmaniasis. In places
where resistance to antimonials is common, such as India,
other common chemotherapeutic treatments include ampho-
tericin B and pentamidine (Croft et al., 2006b; Mishara et al.,
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1940s, only recently was the oral drug miltefosine tested
against leishmaniasis (Sundar et al., 2002). However, the
relative high toxicity and the lack of safe oral drugs still
underline the need for new leishmanicidal drugs.
In the last decades, due to their biological activities,
naturally occurring PAs, analogues, or conjugates have
become of great interest in different research areas (Kar-
igiannis and Papaioannou, 2000). Therefore, the natural PAs
putrescine 1, spermidine 2, and spermine 3 found in high
levels in Leishmania are essential for cell growth and
differentiation in either eukaryotic or prokaryotic cells
(Vannier-Santos et al., 2008). In general, polyamines have
been postulated to have anti-inflammatory and antioxidant
properties (Lagishetty and Naik, 2008). Early studies indi-
cated the mechanism of action of spermine and those may
include inhibition of the cytochrome c reduction initiated by
formyl-Met-Leu-Phe or phorbol myristate acetate-stimulated
human granulocytes, inhibition of the Fe(III)/xanthine
oxidase-stimulated lipid peroxidation of brain phospholipid
liposomes, and inhibition of the Fe(II)-induced depolymer-
ization of hyaluronic acid (Løvaas and Carlin, 1991). It has
been suggested that PAs exert at least 2 different anti-
inflammatory mechanisms: the first one is mediated by the
synthesis of an anti-inflammatory protein (vasoregulin)
(Oyanagui, 1984) and the second one is their direct action
on leucocytes as modulators of calcium-dependent immune
processes (Theoharides, 1980). Furthermore, the specific
Leishmania polyamine metabolism pathway may increase
the chances of a better selectivity in mammalian cells, since
abandoning of the treatment by the patients due to serious
side-effects is a major concern (Croft et al., 2006b).
In this context, synthesized diamino derivative PA
analogues have emerged as promising compounds against
leishmaniasis and other parasitic infections such as malaria.
However, most of the studies reported to date have evaluated
their activity against promastigotes or axenic amastigotes
either in L. amazonensis or in L. infantum (Costa et al., 2009;
Del Olmo et al., 2002; Labadie et al., 2004; Tavares et al.,
2005). This is the first study using PA analogues in the natural
intracellular model of infection. This work described the
synthesis of a series of mono-protected diamines with
t-butyloxycarbonyl (BOC). In order to observe the relative
contribution of these subunits to the leishmanicidal
activities of PA derivatives, the compounds were incubated
in the presence of macrophages containing intracellular
amastigote forms of L. amazonensis. Also, PA derivatives'
cytotoxicity and selective index were estimated using the
human hepatoma HepG2 cell line.2. Materials and methods
2.1. Chemistry
The diamine derivatives were prepared using commercial
diamines and a standard synthetic methodology. Briefly, a0.5 mol/L solution of BOC2O (1 equiv, 1.5 mmol) in CHCl3
was added dropwise to a 0.25 mol/L solution of diamine 1–9
(5 equiv) in CHCl3 at 0 °C. After 24 h at room temperature,
the reaction mixture was filtered and concentrated under
reduced pressure. The residue was solubilized in ethyl
acetate (30 mL), washed with brine (3 × 20 mL), dried
(MgSO4), and concentrated, affording pure mono-BOC-
protected diamine 10–13. Further column chromatography
purification (CHCl3/MeOH, 95:5) was necessary to obtain
compounds 14–18. After column chromatography purifica-
tion on silica gel, the mono-BOC-protected diamine
compounds were obtained in 50–73% yield. Also, a
calculated octanol/water partition coefficient (cLog P) was
obtained for compounds 1–18 by using the online prediction
program provided at the Molinspiration website (http://
www.molinspiration.com).
2.2. Parasite maintenance
The World Health Organization (WHO) reference strain
of L. amazonensis (IFLA/BR/1967/PH8) was used and
typed as previously described (Rocha et al., 2010). To
ensure infectivity, parasites were always kept in BALC/c
mice (Mus musculus) prior to isolation of amastigotes from
foot-pad lesions. Amastigote forms differentiated into
promastigotes were grown at 25 °C in M199 medium
supplemented with 10% heat-inactivated fetal calf serum, 40
mmol/L HEPES, 0.1 mmol/L adenine, 0.0005% hemin,
0.0002% biotin, and 50 U/mL penicillin and 50 mg/mL
streptomycin (Soares et al., 2002).
2.3. Purification of murine peritoneal macrophages and
cell culture
Macrophages and infection were performed as reported
with modifications (Berman and Lee, 1984; Neal and Croft,
1984). BALB/c mice were injected intraperitoneally with
2 ml of 3% sodium thioglycollate medium. After 72 h,
peritoneal macrophages were removed by washing with cold
RPMI 1640 medium and enriched by adherence in round
glass coverslips (13 mm) placed in a 24-well culture plate.
Cells (2 × 105 cells/well) were cultured (37 °C, 5%CO2, 18 h)
in RPMI supplemented with 10% heat-inactivated fetal
bovine serum (FBS) prior to infection with parasites.
Macrophages were exposed to stationary phase promasti-
gotes (2 × 106/well) at a ratio of 1:10. To allow internalization
of parasites, plates were incubated for (37 °C, 5% CO2, 5 h)
and the remaining noninternalized parasites were removed.
2.4. In vitro assay with PA derivatives
The PA derivates and controls were serially diluted with
RPMI 1640 medium supplemented with 10% FBS at final
concentrations of 50, 25, 12.5, 6.25, and 3.12 μg/ml.
Amphotericin B (as the reference antileishmanial drug) was
used at final concentrations of 1, 0.5, 0.25, 0.12, and 0.06
μg/ml. Infected macrophages were exposed daily to the
compounds for 3 consecutive days. After this period,
Table 1
Lipophilicity, in vitro antileishmanial activity, and cytotoxicity of
compounds 1–9 against intracellular amastigotes of L. amazonensis
Compound n cLog Pa IC50
b MLD50
c SId
1 2 −2.08 N50
2 3 −1.81 34.65 ± 13.25 2208.00 ± 1828.00 63.72
3 4 −1.54 N50
4 5 −1.03 N50
5 6 −0.53 N50
6 7 −0.02 N50
7 8 0.48 29.16 ± 16.98 459.00 ± 289.91 15.74
8 10 1.49 19.59 ± 14.97 682.50 ± 0.71 34.84
9 12 2.50 26.34 ± 5.44 439.50 ± 228.40 16.69
a Calculated using the online prediction program at http://www.
molinspiration.com.
b IC50 = Half-maximal inhibitory response in micrograms per milliliter.
c MLD50 = The minimum lethal dose that killed 50% of the cells in
micrograms per milliliter.
d SI = Selective index, calculated based on the IC50/MLD50 ratios.
able 2
ipophilicity, in vitro antileishmanial activity, and cytotoxicity of
ompounds 10–18 against intracellular amastigotes of L. amazonensis
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Pinhais, Brazil), and subsequently mounted with Entellan®
(Merck, Darmstadt, Germany) on glass slides. Negative
control included only infected macrophages and medium.
Incubations were tested in duplicate in 2 independent
experiments (Berman and Lee, 1984; Neal and Croft, 1984).
2.5. Cytotoxicity assay
Cytotoxicity was determined using the MTT method (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide) and the hepatoma cell lineage Hep G2 A16. Cells
were kept in RPMI medium supplemented with 10% FBS,
and confluent monolayers were trypsinized, washed in
RPMI, and applied in 96-well microtiter plates (4 × 104
cells/well). Compounds and amphotericin B in the same
conditions described above were incubated with the cells
(37 °C, 5% CO2, 24 h). Colorimetric reaction was
developed after incubation with MTT (37 °C, 4 h) followed
by addition of acidified isopropanol as previously described
(Denizot and Lang, 1986). The reaction was read
spectrophotometrically with a 570-nm filter and a back-
ground of 630 nm. Incubations were tested in triplicate in 2
independent experiments.
2.6. Analyses
Inhibition of parasite growth and cytotoxicity were
evaluated through the percentage of infected macrophages
(100 cells) and MTT-derived colorimetric values, respec-
tively. Those values were plotted to generate dose–response
curves. The half-maximal inhibitory response (IC50) and the
minimum lethal dose (MLD50) based upon cell growth in
drug-free controls were estimated by curve fitting using the
Microcal Origin Software (Northampton, MA, USA)
(Cunico et al., 2006; Desjardins et al., 1979; Madureira
et al., 2002; Oliveira et al., 2008). The selective indexes (SIs)
were calculated using the MLD50/IC50 ratios (Loset et al.,
2009; Nwada and Hudson, 2006).ompound n cLog Pa IC50
b MLD50
c SId
0 2 −0.063 N50
1 3 0.208 N50
2 4 0.478 N50
3 5 0.984 N50
4 6 1.489 N50
5 7 1.994 N50
6 8 2.499 N50
7 10 3.509 10.39 ± 0.27 106.50 ± 129.40 10.25
8 12 4.520 3.78 ± 0.42 117.00 ± 7.07 30.95
mphotericin B 0.46 ± 0.04 192.50 ± 2.12 418.48
a Calculated using the online prediction program at http://www.
olinspiration.com.
b IC50 = Half-maximal inhibitory response in micrograms per milliliter.
c MLD50 = The minimum lethal dose that killed 50% of the cells in
icrograms per milliliter.
d SI = Selective index, calculated based on the IC50/MLD50 ratios.3. Results
Screening compounds against intracellular amastigote
forms of Leishmania have been used as the classical method
for many years. Although this method is labor intensive and
cannot support automation, direct counting assays enable to
determine the percentage of infected cells and the number of
amastigotes per cell. IC50 values can be ascertained by
monitoring either the reduction in the mean percentage of
infected macrophages or the mean reduction in the number of
amastigotes/macrophages (Sereno et al., 2007). In this work,
based on the percentage of infected macrophages the IC50s
values were calculated. The in vitro antileishmanial
activities, cytotoxicity, selective indexes, and cLog P values
of PA derivatives (1–18) are shown in Tables 1 and 2.
Compounds with IC50 higher than 50 μg/mL wereconsidered inactive against intracellular amastigote forms
of L. amazonensis. On the other hand, compounds 2, 7, 8,
9, 17, and 18 were considered active (IC50's ranging from
3.78 to 34.65 μg/mL) (Fig. 1). Amphotericin B, our
antileishmanial reference drug, exhibited the lowest IC50
value (0.42 μg/mL) (Fig. 2A). It is interesting to note that
an increase in the cLog P values resulted in betterT
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Fig. 1. Synthetic mono-t-butyloxycarbonyl (BOC)-protected diamines with antileishmanial activities.
Fig. 2. Dose–response curves of amphotericin B and polyamine derivative 17 against intracellular Leishmania amazonensis (A and C) and hepatoma HepG2
cells (B and D). IC50 = Half-maximal inhibitory response; MLD50 = the minimum lethal dose. Curves were obtained using Microcal Origin Software. Results are
a representation of 1 experiment.
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and 18 to compounds 2, 7, 8 and 9 (Tables 1 and 2).
Active compounds and amphotericin B were thus selected
for cytotoxicity evaluation against a human hepatoma cell
line (HepG2) (Fig. 2B and D). The results were expressed as
minimal lethal doses (MLD50) prior to calculation of the SI.
The relative selectivity of these compounds against
L. amazonensis compared to HepG2 was calculated based
on MLD50/IC50 ratios (Tables 1 and 2). Among the 6
selected compounds, the best SI value was observed for 2,
followed by 8 and 18. Amphotericin B, our drug control, had
the best SI value as expected. Compounds exhibiting SI
lower than 20 (7, 9, and 17) were considered toxic (Loset et
al., 2009; Nwada and Hudson, 2006) (Tables 1 and 2).4. Discussion
Leishmaniases are considered by the WHO as one of
the major 6 important infectious diseases worldwide (http://
www.who.int/leishmaniasis/en/index.html). At present, a
great interest in developing new drugs, combinations, or
protocols against tropical and neglected diseases has been
stimulated by many initiatives (Moran et al., 2009). In this
context, recent studies using nonantimony treatments (oral
miltefosine, ketoconazole, and liposomal amphotericin B)
were proven to be an effective alternative to pentavalent
antimony for many Leishmania species (Ramanathan et al.,
2011). This may represent an advantage in the use of non–
antimony-based regimens due to their safety, efficacy, and
potentially less toxic effects. Over the past years, the
absence of research and development for new medicines
targeting diseases affecting people in developing countries
has become a global concern (Chirac and Torreele, 2006).
In the case of leishmaniasis, a primarily rural disease, an
increase in its incidence has been increasingly reported in
larger cities (Ashford, 2000). Since there is no available
vaccine and vector/reservoir control has limitations, current
control measures are mainly based on patient treatment.
However, side-effects, treatment failure due to parasite
resistance, HIV co-infection, and intravenous administra-
tion are the major concerns in leishmaniasis chemotherapy
(Croft et al., 2006a,b). Although the introduction of new
therapies such as liposomal amphotericin, oral miltefosine,
and paromomycin occurred in the past decade, these are
not ideal. It is critical that less toxic and cheaper therapies
be developed. Therefore, a search for new chemothera-
peutic compounds against Leishmania is still warranted
(Alvar et al., 2006).
L. amazonensis, the etiologic agent of cutaneous and
diffuse leishmaniasis, is often associated with resistance
against current standard antileishmanial drugs. It is a useful
species for both in vivo and in vitro tests since it is very easy
to keep under laboratory conditions and is a very effective
mouse model. In the search for an alternative antileishmanial
drug, many studies have already determined the activity ofchemical or plant-derived compounds against this species
(Aguiar et al., 2010; García et al., 2010; Junior et al., 2010;
Khouri et al., 2010; Souza-Fagundes et al., 2010).
Polyamine compound derivatives have been tested
against Leishmania by several authors due to their roles
in important biological functions in cell growth and
differentiation (Costa et al., 2009; Del Olmo et al., 2002;
Labadie et al., 2004; Tavares et al., 2005). However,
those studies have evaluated PA antiproliferative activity
only in promastigotes and amastigote-like parasites.
Although the mechanism of action still needs to be
fully elucidated in Leishmania, it is very clear that PA
derivatives can have differential effects depending on the
parasite stage. For example, in promastigotes, the
mechanism is similar to apoptosis observed for metazoan
(Tavares et al., 2005). In our work, we tested for the first
time this class of organic compounds against intracellular
amastigote forms in murine macrophages, a model that
resembles a natural infection.
Consistent with the data from the previous studies, PA
derivatives also exhibited antileishmanial activities inside the
cell. This phenomenon was correlated to the lipophilicity of
the molecules as indicated by cLog P values. Highest
antiproliferative activity against intracellular L. amazonensis
was observed for compounds 17 (Fig. 2C) and 18 (IC50's
between 3.8 and 10.4 μg/mL), and those data could be a result
of their capacity to reach the parasite in the parasitophorous
vacuole. Confirming this idea, we found that compound 2
(cLog P value = −1.81) had a lower ability to kill the parasite,
exhibiting a higher IC50 value (34.65 ± 13.25 μg/mL). These
preliminary results indicate that a longer alkyl chain seems to
be important to the leishmanicidal activity observed. In spite
of having a good antileishmanial activity, compound 17 was
very toxic (SI = 10.25). On the other hand, compound 2 was
the less cytotoxic among all PA derivatives tested (MDL50 =
2208.00 ± 1828.00 μg/mL) followed by compounds
8 (682.50 ± 0.71 μg/mL) and 18 (117.00 ± 7.07 μg/mL),
with respective SIs of 63.72, 34.84, and 30.95. In comparison
to our reference drug, amphotericin B, the SI indexes for these
compounds can be considered low, suggesting limited
selectivity against L. amazonensis infection in vitro. In fact,
Tavares et al. (2005) have demonstrated DNA fragmentation
in L. infantum as one of the apoptotic mechanisms in
promastigotes. Although PA derivatives have antileishmanial
potential, 50% of the active compounds were very cytotoxic
to HepG2 cells.5. Conclusions
A series of 18 protected and nonprotected α,ω-diami-
noalkanes have been evaluated for their in vitro activity
against intracellular amastigote forms of L. amazonensis. In
general, mono-BOC-protected α,ω-diaminoalkanes com-
pounds with longer alkyl chains (H2N(CH2)nNHBoc, n =
10–12) exhibited better leishmanicidal activity when
278 A.C. Pinheiro et al. / Diagnostic Microbiology and Infectious Disease 71 (2011) 273–278compared to the analogous nonprotected compounds.
However, most of the PA derivates exhibited high
cytotoxicity. Moreover, from all compounds tested, 2, 8,
and 18 exhibited the best leishmanicidal activity and highest
SIs. Although compound 18 exhibited the best lipophilicity,
compounds 2 and 8 were less toxic. Their potential for in
vivo tests in mice should be further evaluated.Acknowledgments
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